Progesterone Dose Adjustment with Estradiol Patch Increase

Rationale for Maintaining Current Progesterone Dose

The standard progesterone dosing for endometrial protection is 100-200 mg daily for 12-14 days per month in a sequential regimen, regardless of the specific estradiol dose within the therapeutic range, as recommended by guideline societies, with a strength of evidence based on clinical trials 1, 2
Both 0.0375 mg (37.5 mcg/day) and 0.05 mg (50 mcg/day) estradiol patches fall well within the standard therapeutic range for hormone replacement therapy, according to the American College of Obstetricians and Gynecologists 1, 3

The patient should continue their current regimen of 100 mg progesterone for 12-14 days per month, as recommended by the Endocrine Society 1, 2
If the patient is taking progesterone continuously (daily) rather than cyclically, this is also acceptable and does not require dose adjustment with the estradiol increase, based on evidence from the American College of Obstetricians and Gynecologists 1

Alternative options to micronized progesterone include Dydrogesterone 5-10 mg daily for 12-14 days per month, as recommended by the European Society of Human Reproduction and Embryology 1, 3
Medroxyprogesterone acetate 5-10 mg daily for 12-14 days per month is also an option, though less preferred due to less favorable metabolic profile, according to the American College of Obstetricians and Gynecologists 1

The only scenario requiring progesterone dose evaluation would be if breakthrough bleeding occurs despite adequate progesterone dosing, which would warrant endometrial assessment rather than automatic dose increase, as recommended by the American College of Obstetricians and Gynecologists 1, 2

A 2mg sublingual estradiol dose is approximately equivalent to a 100 mcg/day transdermal estradiol patch, though sublingual administration produces significantly higher estrone levels that may not be therapeutically desirable 4, 5
Adult maintenance dosing for hormone replacement typically requires 100-200 mcg/day transdermal estradiol to achieve therapeutic effect 4, 5

For women with an intact uterus, endometrial protection is mandatory, and micronized progesterone 100-200 mg daily for 12-14 days per month in a sequential regimen is recommended 4, 6
Alternative progestin options include dydrogesterone 5-10 mg daily for 12-14 days per month 4
These progestins are preferred over medroxyprogesterone due to more favorable metabolic profiles 4

Replace 2mg sublingual estradiol with a 100 mcg/day transdermal patch applied twice weekly or weekly depending on formulation 5, 6
If vasomotor symptoms persist after 2-4 weeks, increase to 150-200 mcg/day patch 5
Assess symptom relief at 4-6 weeks after conversion 5

Do not forget progestin in women with intact uteri, as unopposed estrogen increases endometrial cancer risk 4, 6
Monitor for under-treatment in the first month after conversion, as some patients may require higher patch doses to match their previous symptom control 5